EGFR and neoplasm: The tumor inhibition achieved with the anti-EGFR antibody cetuximab, though not statistically significant, was comparable to or less pronounced than EGFRvIII/CD3 TandAb, despite the fact that cetuximab was administered at a 10- to 100-fold higher dose (1 mg/injection) twice weekly (Figure 6A).